



Submitted by: Chief Medical Officer
Name: Johnathan Lancaster, MD, PhD
Company/Organization: Myriad Genetic Laboratories, Inc.
Address: 320 Wakara Way, Salt Lake City, UT 84108
Phone: 801-505-5090
Email: jlancaster@myriad.com
Date of request: October 1, 2017
NCCN Guidelines Panel: Genetic/Familial High Risk Assessment – Colorectal

Specific Changes: On page HRS-3, add the following bullet point to the list of criteria for “EVALUATION TO EXCLUDE LYNCH SYNDROME”:

- An individual with a colorectal tumor with MSI-H histology (i.e., presence of tumor-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern) in a patient younger than 60 years.

FDA Clearance: Not applicable.

Rationale: The criteria listed on page HRS-3 largely mirror the Bethesda criteria described on page MS-5, but lack mention of MSI-H histology, which could be relevant in some cases.

Sincerely,

A handwritten signature in black ink, appearing to be "J. Lancaster", written over a circular scribble.

Johnathan Lancaster, MD, PhD
Chief Medical Officer, Myriad Genetic Laboratories Inc.